Trevi Therapeutics, Inc. Gains 36.11%

Tue, Mar 01, 2022 at 05:30 PM

Trevi Therapeutics, Inc. (TRVI:NASDAQ) soared at $0.87, representing a gain of 36.1%. On Mon, Feb 28, 2022, TRVI:NASDAQ hit a New 2-Week High of $0.64. The stock appeared on our News Catalysts scanner on Thu, Feb 24, 2022 at 08:17 AM in the 'BIOTECH' category. From Tue, Feb 15, 2022, the stock recorded 50.00% Up Days and 44.44% Green Days

About Trevi Therapeutics, Inc. (TRVI:NASDAQ)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Top 10 Gainers:

Viscogliosi Brothers Acquisition Corp (VBOC:NASDAQ), 100%
Avenue Therapeutics, Inc. (ATXI:NASDAQ), 78.46%
CTI BioPharma Corp. (CTIC:NASDAQ), 63.16%
GBS Inc. (GBS:NASDAQ), 50%
Guardion Health Sciences, Inc. (GHSI:NASDAQ), 47.84%
CooTek (Cayman) Inc. (CTK:NYSE), 36.24%
Trevi Therapeutics, Inc. (TRVI:NASDAQ), 36.11%
Sky Harbour Group Corporation Class A (SKYH:NYSEMKT), 30.84%
GWG Holdings, Inc. (GWGH:NASDAQ), 29.37%
Avinger, Inc. (AVGR:NASDAQ), 28.31%